These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26026260)

  • 1. Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma.
    Van Keerberghen CA; Jean-Baptiste J; Wolter P; Zucman-Rossi J; Schöffski P; Beuselinck B
    Clin Genitourin Cancer; 2015 Dec; 13(6):e407-10. PubMed ID: 26026260
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
    Teo M; Downey FP; McDermott RS
    Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
    Nicholaou T; Wong R; Davis ID
    Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
    Gyawali B; Ando Y
    Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
    [No Abstract]   [Full Text] [Related]  

  • 5. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
    Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
    Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
    Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of antiangiogenic therapy-induced hypertension.
    de Jesus-Gonzalez N; Robinson E; Moslehi J; Humphreys BD
    Hypertension; 2012 Sep; 60(3):607-15. PubMed ID: 22851729
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.
    Michaelson MD; Iliopoulos O; McDermott DF; McGovern FJ; Harisinghani MG; Oliva E
    N Engl J Med; 2008 May; 358(22):2389-96. PubMed ID: 18509125
    [No Abstract]   [Full Text] [Related]  

  • 10. Alternative sunitinib schedules in metastatic renal cell carcinoma and the RAINBOW study.
    Bracarda S;
    Ann Oncol; 2015 Jul; 26(7):1512-3. PubMed ID: 25846555
    [No Abstract]   [Full Text] [Related]  

  • 11. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Sun M; Trinh QD; Perrotte P; Karakiewicz PI
    Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500
    [No Abstract]   [Full Text] [Related]  

  • 12. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Ouzaid I; Rini B
    Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
    Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
    Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
    [No Abstract]   [Full Text] [Related]  

  • 15. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
    Thibault F; Billemont B; Rixe O
    J Neurooncol; 2008 Jan; 86(2):243-4. PubMed ID: 17634858
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
    Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK
    N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224
    [No Abstract]   [Full Text] [Related]  

  • 18. Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?
    Gambini D; Locatelli E; Gianelli U; Bareggi C; Galassi B; Visintin R; Massironi S; Dell'orto PG; Tomirotti M
    Anticancer Res; 2014 Dec; 34(12):7361-5. PubMed ID: 25503173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presurgical treatment with sunitinib for renal cell carcinoma with a level III/IV vena cava tumour thrombus.
    Horn T; Thalgott MK; Maurer T; Hauner K; Schulz S; Fingerle A; Retz M; Gschwend JE; Kübler HR
    Anticancer Res; 2012 May; 32(5):1729-35. PubMed ID: 22593453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.